MAP2K7 and hematologic disorder: Indeed, the MEK/ERK signaling pathway has been suggested to be associated with resistance to HDACi both in solid tumors and hematological malignancies.7, 8, 41, 42 However, these studies address acquired resistance to HDACi following exposure to chemotherapeutic agents, rather than inherent resistance to HDACi.